Fundraising FoxAxoSim
New Orleans, US · Founded 2018 · Delaware corporation · 1 known investors
Find your way into AxoSim
Each arrow is one introduction. Sign up to fill in the first one.
151 people can intro you to J.
Ask Saeju Jeong to introduce you to J. Lowry Curley
You →Saeju · together at Foundation for the National Institutes of Health →J.
Sign up to find every way you can get introduced to AxoSim
- Your email: who you already know at AxoSim, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the AxoSim team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
AxoSim was founded in 2018 by J. Lowry Curley and Michael Moore.
JL
J. Lowry CurleyCo-founderJ. Lowry Curley founded AxoSim, which develops organ-on-a-chip and organoid platforms for neurobiological research and drug testing. Over two decades, he has worked in tissue engineering, bioelectronics, and AI-driven analytics, and previously directed technology licensing from academic institutions including Johns Hopkins, UCSD, and Tulane.
AS
Alif SalehExecutive
BC
Benjamin CappielloNamed on SEC filing
JS
Jeffrey SilvermanNamed on SEC filing
MM
Monica MeteaNamed on SEC filing
Board
DP
Dale PfostBoard director
DW
David WeinerBoard director
MK
Michael KatzBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$17.4M disclosed across 4 rounds · 2019–2025
▶$6.5MraisedJan 2026 · 8 investors · BiotechnologyRule 506(b)
▶$6.5MraisedJan 2026 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Miklos KoborDirector
- Michael KatzDirector
- Dale PfostDirector
- Alif SalehExecutive Officer, Director
- David WeinerDirector
- Offering amount
- $7M
- Amount sold
- $6.5M
- Sales commissions
- $170K
- Placement agents
- Ian Dunn
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.7MraisedNov 2024 · 21 investors · BiotechnologyRule 506(b)
▶$3.7MraisedNov 2024 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dale PfostDirector
- David WeinerDirector
- Alif SalehExecutive Officer, Director
- Michael KatzDirector
- J. Lowry CurleyExecutive Officer, Director
- Offering amount
- $4.8M
- Amount sold
- $3.7M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.1MraisedJun 2021 · 12 investors · BiotechnologyRule 506(b)
▶$6.1MraisedJun 2021 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin CappielloExecutive Officer
- Jeffrey SilvermanDirector
- Dale PfostDirector
- Monica MeteaExecutive Officer
- Michael KatzDirector
- J. Lowry CurleyExecutive Officer, Director
- Michael MooreExecutive Officer
- Offering amount
- $6.1M
- Amount sold
- $6.1M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$1.1MraisedMar 2019 · 13 investors · BiotechnologyRule 506(b)
▶$1.1MraisedMar 2019 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael MooreDirector
- Jeffrey SilvermanDirector
- Lowry CurleyExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $1.1M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $299.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $227.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $197.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2017 | $2.1M |
| National Science Foundation | Phase ISTTR | 2016 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $224.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- Who founded AxoSim?
- AxoSim was founded by J. Lowry Curley, Michael Moore in 2018.
- Who are AxoSim's investors?
- AxoSim's investors include New Orleans Startup Fund.
- How much funding has AxoSim raised?
- AxoSim has disclosed $17.4M raised across 4 rounds.
- Where is AxoSim headquartered?
- AxoSim is headquartered in New Orleans, US.